These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vitro susceptibility of Mycobacterium tuberculosis to fusidic acid. Cicek-Saydam C; Cavusoglu C; Burhanoglu D; Hilmioglu S; Ozkalay N; Bilgic A Clin Microbiol Infect; 2001 Dec; 7(12):700-2. PubMed ID: 11843915 [TBL] [Abstract][Full Text] [Related]
3. Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization - Insight from DFT calculations, molecular docking and molecular dynamics simulations. Akinpelu OI; Lawal MM; Kumalo HM; Mhlongo NN Tuberculosis (Edinb); 2020 Mar; 121():101920. PubMed ID: 32279872 [TBL] [Abstract][Full Text] [Related]
4. Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery. Kigondu EM; Wasuna A; Warner DF; Chibale K Bioorg Med Chem; 2014 Aug; 22(16):4453-61. PubMed ID: 24997576 [TBL] [Abstract][Full Text] [Related]
5. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
6. Hyper-susceptibility of a fusidic acid-resistant mutant of Salmonella to different classes of antibiotics. Macvanin M; Hughes D FEMS Microbiol Lett; 2005 Jun; 247(2):215-20. PubMed ID: 15935566 [TBL] [Abstract][Full Text] [Related]
7. Identification and validation of novel drug targets in Mycobacterium tuberculosis. Singh V; Mizrahi V Drug Discov Today; 2017 Mar; 22(3):503-509. PubMed ID: 27649943 [TBL] [Abstract][Full Text] [Related]
8. Novel Antimicrobials from Uncultured Bacteria Acting against Mycobacterium tuberculosis. Quigley J; Peoples A; Sarybaeva A; Hughes D; Ghiglieri M; Achorn C; Desrosiers A; Felix C; Liang L; Malveira S; Millett W; Nitti A; Tran B; Zullo A; Anklin C; Spoering A; Ling LL; Lewis K mBio; 2020 Aug; 11(4):. PubMed ID: 32753498 [No Abstract] [Full Text] [Related]
9. Semisynthetic Antimycobacterial C-3 Silicate and C-3/C-21 Ester Derivatives of Fusidic Acid: Pharmacological Evaluation and Stability Studies in Liver Microsomes, Rat Plasma, and Njoroge M; Kaur G; Espinoza-Moraga M; Wasuna A; Dziwornu GA; Seldon R; Taylor D; Okombo J; Warner DF; Chibale K ACS Infect Dis; 2019 Sep; 5(9):1634-1644. PubMed ID: 31309823 [TBL] [Abstract][Full Text] [Related]
10. [Prospects for development of new antituberculous drugs]. Tomioka H Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850 [TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
12. Susceptibility of strains of the Mycobacterium tuberculosis complex to fusidic acid. Fuursted K; Askgaard D; Faber V APMIS; 1992 Jul; 100(7):663-7. PubMed ID: 1642855 [TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship analyses of fusidic acid derivatives highlight crucial role of the C-21 carboxylic acid moiety to its anti-mycobacterial activity. Singh K; Kaur G; Shanika PS; Dziwornu GA; Okombo J; Chibale K Bioorg Med Chem; 2020 Jul; 28(13):115530. PubMed ID: 32362386 [TBL] [Abstract][Full Text] [Related]
14. [Recent progress in mycobacteriology]. Okada M; Kobayashi K Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602 [TBL] [Abstract][Full Text] [Related]
15. New frontiers in the therapy of tuberculosis: fighting with the global menace. Chhabria M; Jani M; Patel S Mini Rev Med Chem; 2009 Apr; 9(4):401-30. PubMed ID: 19356120 [TBL] [Abstract][Full Text] [Related]
16. Drug resistance mechanisms and novel drug targets for tuberculosis therapy. Islam MM; Hameed HMA; Mugweru J; Chhotaray C; Wang C; Tan Y; Liu J; Li X; Tan S; Ojima I; Yew WW; Nuermberger E; Lamichhane G; Zhang T J Genet Genomics; 2017 Jan; 44(1):21-37. PubMed ID: 28117224 [TBL] [Abstract][Full Text] [Related]
17. Validation of Mycobacterium tuberculosis dihydroneopterin aldolase as a molecular target for anti-tuberculosis drug development. Falcão VC; Villela AD; Rodrigues-Junior VS; Pissinate K; Eichler P; Pinto AF; Basso LA; Santos DS; Bizarro CV Biochem Biophys Res Commun; 2017 Apr; 485(4):814-819. PubMed ID: 28257847 [TBL] [Abstract][Full Text] [Related]
19. Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis. Nguyen PC; Delorme V; Bénarouche A; Guy A; Landry V; Audebert S; Pophillat M; Camoin L; Crauste C; Galano JM; Durand T; Brodin P; Canaan S; Cavalier JF Bioorg Chem; 2018 Dec; 81():414-424. PubMed ID: 30212765 [TBL] [Abstract][Full Text] [Related]
20. [Construction of EF-G knockdown strain of DI Y; Bai J; Chi M; Fan W; Zhang X Sheng Wu Gong Cheng Xue Bao; 2022 Mar; 38(3):1050-1060. PubMed ID: 35355473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]